In metastatic NSCLC, recognized predictive biomarkers for immunotherapy response include PD-L1 tumor proportion score, microsatellite instability (MSI)/deficient mismatch repair (dMMR), and tumor mutational burden (TMB). The gene discussed is CD274; the disease is non-small cell lung carcinoma.